Aims: Hypoglycaemia causes abnormal cardiac repolarisation, which has been related to sympathoadrenal activation. We examined whether individuals with type 1 diabetes (T1D) and impaired awareness of hypoglycaemia (IAH) were protected against proarrhythmogenic alterations on their electrocardiogram during clinical episodes of hypoglycaemia.
Methods: Adults with T1D and IAH underwent 96 h of simultaneous ambulatory electrocardiogram and blinded continuous interstitial glucose (IG) monitoring. Measures of cardiac repolarisation and heart rate variability (HRV) were compared during hypoglycaemia versus time and person-matched euglycaemia. We compared these data to a historical control group of individuals with T1D and no IAH.
Results: Fourteen individuals (10/14 female) with a mean (SD) age of 39 (10) years and T1D duration of 24 (9) years were examined. Fourteen daytime and 12 nocturnal hypoglycaemic episodes were analysed. During daytime hypoglycaemia versus euglycaemia, the mean (SD) QT interval was prolonged to 443 (38) versus 422 (27) ms, p = 0.027; the Tpeak-to-Tend interval was prolonged to 93 (18) versus 77 (9) ms, p = 0.002; and the T wave area symmetry decreased to 1.19 (0.37) versus 1.39 (0.23), p = 0.014. High-frequency power decreased during daytime hypoglycaemia versus euglycaemia to 1.66 (0.41) versus 1.92 (0.52), p = 0.038. At daytime, the Tpeak-to-Tend interval decreased significantly more (hypoglycaemia vs. euglycaemia) in the IAH group in comparison to the decrease observed in the historical control group of T1D individuals without IAH (p for interaction 0.005). Cardiac arrhythmias were infrequent and of no clinical significance.
Conclusions: Hypoglycaemia can still lead to proarrhythmogenic electrocardiographic changes in individuals with T1D and IAH. We observed diurnal, inter- and intraindividual variability in responses to hypoglycaemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dme.70019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics and pharmacodynamics of insulin lispro 25 versus the original preparation (Humalog25) in Chinese healthy male volunteers.
Front Pharmacol
February 2025
Phase I Clinical Trial Center, Bishan Hospital of Chongqing, Bishan Hospital of Chongqing Medical University, Chongqing, China.
There are approximately 537 million adults with diabetes worldwide, and insulin still plays an important role in its treatment. However, the long-term use of insulin imposes a significant financial burden on patients. This study aims to explore the pharmacokinetic (PK)/ pharmacodynamic (PD) parameters of generic premixed insulin lispro 25 (25% insulin lispro and 75% protamine zinc lispro) and evaluate the bio-equivalence between generic and brand-name preparations to reduce medical costs while ensuring the effectiveness and safety of treatment.
View Article and Find Full Text PDFSafety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study.
Adv Ther
March 2025
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Introduction: In this post-marketing study in Japan, the occurrence of hospital-treated hypoglycaemia and severe hyperglycaemia requiring inpatient treatment was evaluated in various cohorts of people with type 2 diabetes (T2D) newly switched to iGlarLixi, a titratable, once-daily, fixed-ratio combination of long-acting insulin glargine 100 U/mL (iGlar-100) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA, lixisenatide).
Methods: In this retrospective, observational study, acute-care hospital data from adults with T2D were analysed from the Medical Data Vision database. In Cohort 1, the incidence rate of hospital-treated hypoglycaemia following newly prescribed iGlarLixi versus iGlar-100 was assessed.
Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.
Acta Ophthalmol
March 2025
Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark.
This review covers a seminal study of the relation between exposure to the glucagon-like peptide 1 (GLP-1) agonist semaglutide and incident non-arteritic anterior ischaemic optic neuropathy (NAION) in a neuro-ophthalmology clinic setting, subsequent studies in unselected populations, a meta-analysis of clinical trials and pathophysiology studies of the optic disc and retina that may help elucidate the relation between semaglutide and NAION in patients with diabetes or obesity. In the matched cohort study of neuro-ophthalmology patients, those treated using agents other than semaglutide had NAION rates, orders of magnitude higher than a background population, presumably because referral patterns led to the enrichment of the study populations with patients at high risk of NAION. With semaglutide, the rates of NAION were 4.
View Article and Find Full Text PDFImmune dysregulation in glycogen storage disease 1b extends beyond neutropenia.
Hum Immunol
March 2025
Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA; Department of Obstetrics, Gynecology and Reproductive Sciences, New Haven, CT, USA; Program in Human and Translational Immunology Yale School of Medicine, New Haven, CT, USA. Electronic address:
Glycogen Storage Disease type 1b (GSD1b) is a rare disease manifesting as hypoglycemia, recurrent infections and neutropenia, resulting from deleterious mutations in the SLC37A4 gene encoding the glucose-6-phosphate transporter. Classic treatment strategies in GSD1b focus on restoring neutrophil numbers and function; however, the immune defect is believed to be multifactorial and extensive immunophenotyping characterization is currently missing. Here we apply a systems immunology approach utilizing Cytometry by Time of Flight (CyTOF) to map the peripheral immune landscape of 6 GSD1b patients.
View Article and Find Full Text PDFEffects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trial.
Nephrol Dial Transplant
February 2025
Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.
Background: Insulin is a mainstay treatment for diabetes, but its use is associated with weight gain and hypoglycaemia. Data on the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on insulin use in people with chronic kidney disease (CKD) is limited.
Methods: We conducted a post-hoc analysis of the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!